MetaCap

GridAI Technologies (GRDX) vs NextCure (NXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GridAI Technologies (GRDX) has outperformed NextCure (NXTC) over the past year, gaining 20.6% versus a loss of 38.6%. Over five years, NXTC leads with a -91.1% price change compared with -100.0% for GRDX. GridAI Technologies is the larger company by market cap ($32.4 million vs $29.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRDX+20.61%NXTC-38.63%
+172%+37%-97%
Nov 21, 20251 yearNov 20, 2026
GRDX-99.99%NXTC-90.73%
+12%-47%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRDX versus NXTC key metrics
MetricGRDXNXTC
Share price$3.16$6.45
Market cap$32.44M$29.53M
1-day change-8.41%-4.87%
YTD return-32.19%-54.55%
1-year return+20.61%-38.63%
5-year return-99.99%-91.07%
EPS (TTM)$-5.65$-6.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$36.25K—
Net income (latest FY)$-6.39M$-55.84M
Gross margin-1813.56%—
Operating margin-19539.98%—
Net margin-17634.42%—
52-week high$6.93$15.74
52-week low$1.87$1.55
Distance from 52-week high-54.39%-59.02%
Analyst consensus—none
Avg. price target upside—+210.08%
Average volume120.78K79.46K
Shares outstanding10.27M4.58M
Employees—40
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRDX has outperformed NXTC by 59.2 percentage points over the past year.

About GridAI Technologies

GRDX stock →

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.

Health Care · Biotechnology: Pharmaceutical Preparations

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

GRDX vs NXTC FAQ

Which is bigger, GridAI Technologies or NextCure?

GridAI Technologies (GRDX) is larger, with a market capitalization of $32.44M compared with $29.53M for NextCure (NXTC).

Which stock has performed better over the past year, GRDX or NXTC?

GRDX returned +20.61% over the past 12 months, compared with -38.63% for NXTC (price return, excluding dividends). Past performance does not predict future results.

Are GridAI Technologies and NextCure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons